抛售后，个人对Piper Sandler持乐观看法

After losing over a third of its value over the past 30 days, Indivior (NASDAQ:INDV) won a bullish rating on Wall Street as Piper Sandler launched its coverage with an overweight recommendation and a $22 per share target.

Shares of Indivior (INDV) sold off in early July after the U.K.-based drugmaker lowered its FY 2024 financial outlook, citing, mainly, sales headwinds related to Sublocade, its once-monthly injectable indicated for opioid use disorder (OUD).

INDV's 2024 Sublocade sales guidance (cut to $765M-$805M from $820M-$880M) continues to suggest a 25% YoY growth at the midpoint, Piper Analyst David Amsellem wrote, adding that the management guidance of over $1.5B peak sales for the treatment "is credible."

Citing a survey of 25 addiction specialists, the firm noted that the market dynamics for injectable OUD therapies, where Indivior's (INDV) rival Braeburn also operates, are not a "zero-sum game."

Amsellem also highlighted the company's newly launched opioid overdose therapy, Opvee. "These are admittedly early days, though we believe the product can emerge as a meaningful secondary driver," with over $100M in sales contribution, the analyst added.